Cite
Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort
MLA
Elifnur Yay Donderici, et al. “Impact of STK11 Mutation on First-Line Immune Checkpoint Inhibitor (ICI) Outcomes in a Real-World KRAS G12C Mutant Lung Adenocarcinoma Cohort.” Journal of Clinical Oncology, vol. 39, May 2021, p. 9106. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........72be5f790dc11260b1fd3959e55541b6&authtype=sso&custid=ns315887.
APA
Elifnur Yay Donderici, Kathryn Lang, Beata Korytowsky, Junhua Yu, James G. Christensen, Rebecca S. Heist, Nicole Zhang, Andrew S. Chi, & Carin R. Espenschied. (2021). Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort. Journal of Clinical Oncology, 39, 9106.
Chicago
Elifnur Yay Donderici, Kathryn Lang, Beata Korytowsky, Junhua Yu, James G. Christensen, Rebecca S. Heist, Nicole Zhang, Andrew S. Chi, and Carin R. Espenschied. 2021. “Impact of STK11 Mutation on First-Line Immune Checkpoint Inhibitor (ICI) Outcomes in a Real-World KRAS G12C Mutant Lung Adenocarcinoma Cohort.” Journal of Clinical Oncology 39 (May): 9106. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........72be5f790dc11260b1fd3959e55541b6&authtype=sso&custid=ns315887.